Android app on Google Play

StreetInsider.com Pre-Open Movers 12/21: (ASCA) (RHT) (NKE) Higher; (HEB) (ECTE) (RIMM) Lower (more...)

December 21, 2012 9:31 AM EST Send to a Friend
Hemispherx Biopharma, Inc. (NYSE: HEB) 33% LOWER; fails to win FDA panel backing for Ampligen efficacy

Ameristar Casinos, Inc. (Nasdaq: ASCA) 17% HIGHER; Pinnacle Entertainment, Inc. (NYSE: PNK) will acquire all of the outstanding common shares of Ameristar for $26.50 per share in cash, for a total enterprise value of $2.8 billion, including debt of $1.9 billion and cash on hand of $116 million as of September 30, 2012.

Echo Therapeutics, Inc. (Nasdaq: ECTE) 17% LOWER; announced the pricing of a previously announced underwritten public offering of 3,200,000 shares of its common stock, offered at a price to the public of $0.95 per share. The gross proceeds to Echo from this offering are expected to be approximately $3.0 million, before deducting the underwriting discount and other estimated offering expenses payable by Echo. Echo Therapeutics has granted the underwriters a 45-day option to purchase up to an aggregate of 480,000 additional shares of its common stock to cover over-allotments, if any. The offering is expected to close on or about December 27, 2012, subject to customary closing conditions.

Research In Motion Ltd (NASDAQ: RIMM) 16% LOWER; reported Q3 EPS of ($0.22), $0.13 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $2.7 billion versus the consensus estimate of $2.66 billion. Cash increase of approximately $600 million to $2.9 billion.
Halozyme Therapeutics, Inc. (Nasdaq: HALO) 17% HIGHER; entered into a worldwide Collaboration and License Agreement with Pfizer Inc. (NYSE: PFE) for the purpose of developing and commercializing products combining proprietary Pfizer biologics with Halozyme's Enhanzeâ„¢ technology. Enhanze is Halozyme's proprietary drug delivery platform and is based on the Company's patented recombinant human hyaluronidase enzyme (rHuPH20).

Red Hat, Inc. (NYSE: RHT) 6% HIGHER; reported Q3 EPS of $0.29, in-line with the analyst estimate of $0.29. Revenue for the quarter came in at $344 million versus the consensus estimate of $337.57 million. Sees Q4 non-GAAP EPS $0.29-$0.30 vs. the street estimate of $0.30.

Horizon Pharma (Nasdaq: HZNP) 6% HIGHER; announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA), based on the favorable recommendation of their Commission on Human Medicines (CHM), will grant a Marketing Authorization (MA) for DUEXIS (ibuprofen/famotidine), pending review of updated licensing documents which the Company has provided to the MHRA. The MA of DUEXIS is for the treatment of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and to decrease the risk of developing upper gastrointestinal ulcers. DUEXIS is approved and available in the United States.

Micron Technology, Inc. (NASDAQ: MU) 5% LOWER; reported Q3 EPS of ($0.27), $0.08 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $1.88 million versus the consensus estimate of $2.02 million.

Nike Inc. (NYSE: NKE) 4% HIGHER; reported Q2 EPS of $1.14, $0.14 better than the analyst estimate of $1.00. Revenue for the quarter came in at $5.96 billion versus the consensus estimate of $5.99 billion.

Tibco Software, Inc. (NASDAQ: TIBX) 4% HIGHER; reported Q4 EPS of $0.42, $0.03 better than the analyst estimate of $0.39. Revenue for the quarter came in at $296.5 million versus the consensus estimate of $298.09 million.

Amicus Therapeutics, Inc. (NASDAQ: FOLD) 3% LOWER; downgraded at Wedbush

Walgreen Company (NYSE: WAG) 2% LOWER; reported Q1 EPS of $0.58, $0.12 worse than the analyst estimate of $0.70. Revenue for the quarter came in at $17.32 billion versus the consensus estimate of $17.5 billion.

Discover Financial Services (NYSE: DFS) 2% LOWER; FBR Capital downgraded Discover Financial from Outperform to Market Perform

Facebook, Inc. (NASDAQ: FB) 2% LOWER; backpedals on Instagram terms of use changes.

Calamp Corp. (NASDAQ: CAMP) 1% HIGHER; reported Q3 EPS of $0.17, $0.05 better than the analyst estimate of $0.12. Revenue for the quarter came in at $44.3 million versus the consensus estimate of $43.27 million.




You May Also Be Interested In


Related Categories

Special Reports

Add Your Comment